董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Catherine Moukheibir | 女 | Independent Director | 66 | 28.68万 | 4.72 | 2026-02-28 |
| Spike Loy | 男 | Lead Independent Director | 46 | 27.68万 | 2.57 | 2026-02-28 |
| Andrew J. Phillips | 男 | Independent Director | 56 | 28.03万 | 7.07 | 2026-02-28 |
| Jorge Santos da Silva | 男 | Chief Executive Officer,Director and Interim Chair of the Board | 48 | 494.32万 | 307.49 | 2026-02-28 |
| Ramnik Xavier | 男 | Independent Director | 63 | 29.93万 | 7.07 | 2026-02-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jorge Santos da Silva | 男 | Chief Executive Officer,Director and Interim Chair of the Board | 48 | 494.32万 | 307.49 | 2026-02-28 |
| Matthias Bodenstedt | 男 | Chief Financial Officer | 37 | 469.26万 | 127.63 | 2026-02-28 |
| Kristian Reich | 男 | Chief Scientific Officer | 59 | 479.55万 | 304.48 | 2026-02-28 |
董事简历
中英对照 | 中文 | 英文- Catherine Moukheibir
-
Catherine Moukheibir，她一直担任Orphazyme A/S董事（2017年11月以来）。她目前担任MedDay Pharmaceuticals SA的董事会主席和首席执行官，以及Genkyotex SA、Ironwood Pharmaceuticals, Inc.和Kymab Ltd.的董事会成员。在此之前，她曾担任Innate Pharma SA的高级财务顾问和执行董事会成员（从2011年3月到2016年12月），并担任Movetis N.V。的首席财务官（从2008年到2010年，该公司被收购）。从2001年到2007年，她曾担任Zeltia Group S.A.的资本市场主管。除了在MedDay的董事会任职，她还在Orphazyme A/S、Genkyotex SA和Kymab Group Limited的董事会任职。她还曾担任Ablynx NV、Cerenis Therapeutics SA和Creabilis S.A.Ms的董事会董事。Moukheibir拥有耶鲁大学经济学硕士学位和工商管理硕士学位。
Catherine Moukheibir,most recently served as chief executive officer of MedDay Pharmaceuticals, or MedDay, a biopharmaceutical company that focused on nervous system disorders, from 2019 to January 2021. She was also the chair of the board of directors of MedDay from 2016 to January 2021.Prior to that, Ms. Moukheibir served as the senior advisor for finance and a member of the executive board of directors at Innate Pharma SA, an oncology company, from 2011 to 2016, and as the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired.Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007.Ms. Moukheibir currently serves on the board of directors of MoonLake Immunotherapeutics AG (Nasdaq: MLTX), a public company. Ms. Moukheibir also serves as chair of the board of directors of Synthon B.V. and serves on the board of directors of Esteve Healthcare, S.L., Noema Pharma AG and CMR Surgical, all of which are privately held companies. She held past directorships on the boards of directors of Asceneuron SA, Biotalys NV, Creabilis S.A., DNA Script SAS, GenKyoTex S.A., Kymab Group Limited, Orphazyme A/S, Oxford Biomedica plc and Zealand Pharma A/S.Ms. Moukheibir has an M.A. in economics and an M.B.A. from Yale University. - Catherine Moukheibir，她一直担任Orphazyme A/S董事（2017年11月以来）。她目前担任MedDay Pharmaceuticals SA的董事会主席和首席执行官，以及Genkyotex SA、Ironwood Pharmaceuticals, Inc.和Kymab Ltd.的董事会成员。在此之前，她曾担任Innate Pharma SA的高级财务顾问和执行董事会成员（从2011年3月到2016年12月），并担任Movetis N.V。的首席财务官（从2008年到2010年，该公司被收购）。从2001年到2007年，她曾担任Zeltia Group S.A.的资本市场主管。除了在MedDay的董事会任职，她还在Orphazyme A/S、Genkyotex SA和Kymab Group Limited的董事会任职。她还曾担任Ablynx NV、Cerenis Therapeutics SA和Creabilis S.A.Ms的董事会董事。Moukheibir拥有耶鲁大学经济学硕士学位和工商管理硕士学位。
- Catherine Moukheibir,most recently served as chief executive officer of MedDay Pharmaceuticals, or MedDay, a biopharmaceutical company that focused on nervous system disorders, from 2019 to January 2021. She was also the chair of the board of directors of MedDay from 2016 to January 2021.Prior to that, Ms. Moukheibir served as the senior advisor for finance and a member of the executive board of directors at Innate Pharma SA, an oncology company, from 2011 to 2016, and as the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired.Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007.Ms. Moukheibir currently serves on the board of directors of MoonLake Immunotherapeutics AG (Nasdaq: MLTX), a public company. Ms. Moukheibir also serves as chair of the board of directors of Synthon B.V. and serves on the board of directors of Esteve Healthcare, S.L., Noema Pharma AG and CMR Surgical, all of which are privately held companies. She held past directorships on the boards of directors of Asceneuron SA, Biotalys NV, Creabilis S.A., DNA Script SAS, GenKyoTex S.A., Kymab Group Limited, Orphazyme A/S, Oxford Biomedica plc and Zealand Pharma A/S.Ms. Moukheibir has an M.A. in economics and an M.B.A. from Yale University.
- Spike Loy
-
Spike Loy自2020年11月以来一直担任我们的董事会成员。Loy先生目前是BVF Partners LP的董事总经理，自2009年以来一直担任各种职务。Loy先生拥有斯坦福大学人类生物学学士学位和哈佛法学院法学博士学位。
Spike Loy has served as a member of our board of directors since November 2020. Mr. Loy is currently Managing Director of BVF Partners LP, where he has served in various capacities since 2009. Mr. Loy holds a B.A. in human biology from Stanford University and a J.D. from Harvard Law School. - Spike Loy自2020年11月以来一直担任我们的董事会成员。Loy先生目前是BVF Partners LP的董事总经理，自2009年以来一直担任各种职务。Loy先生拥有斯坦福大学人类生物学学士学位和哈佛法学院法学博士学位。
- Spike Loy has served as a member of our board of directors since November 2020. Mr. Loy is currently Managing Director of BVF Partners LP, where he has served in various capacities since 2009. Mr. Loy holds a B.A. in human biology from Stanford University and a J.D. from Harvard Law School.
- Andrew J. Phillips
-
Andrew J.Phillips担任我们的首席财务官。Phillips博士是Cormorant的董事总经理。他还担任Blossom Bioscience Ltd.的首席执行官。Phillips博士是Onkure，Inc.，Expansion Therapeutics，Inc.，Bivacor，Inc.，Blossom Bioscience，Ltd.，Blossom Biomedicines USA，Inc.和Enliven Therapeutics，Inc.的董事会成员。从2016年到2020年，Phillips博士在C4 Therapeutics, Inc.工作，该公司是一家临床阶段的生物制药公司，专注于治疗癌症和其他疾病，最近的职务是从2018年到2020年担任首席执行官。从2014年到2016年，他担任生物医学和基因组研究组织Broad Institute的治疗学发展中心的高级总监。从2010年到2015年，Phillips博士担任耶鲁大学的化学教授，从2001年到2010年，他担任科罗拉多大学的助理教授，副教授和化学与生物化学教授。他拥有新西兰坎特伯雷大学的生物化学理学士学位和化学博士学位。
Andrew J. Phillips has served as a Managing Director at Cormorant Asset Management, an investment manager, since August 2020. Since April 2021 he has also served as Chief Financial Officer of Helix and since June 2021 he has also served as Chief Executive Officer of Blossom Bioscience Ltd., and since December 2021 he has also served as interim Chief Executive Officer of Aleksia Therapeutics Inc. Dr. Phillips is a Director at the following private companies: OnKure, Inc., Expansion Therapeutics, Inc., BiVACOR, Inc., Blossom Bioscience, Ltd, Blossom Biomedicines USA, Inc., ONK Therapeutics, Ltd., Kestrel Therapeutics Inc., and Enliven Therapeutics, Inc. Dr. Phillips previously served as a Director at Elevation Oncology, Inc. from November 2020 through June 2021 and Immuneering Corp from December 2020 through July 2021. From January 2016 to March 2020 Dr. Phillips was with C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for the treatment of cancer and other diseases, where he served as Chief Executive Officer from May 2018 to March 2020 President from September 2016 to May 2018 and Chief Scientific Officer from January 2016 to May 2018. From July 2014 to January 2016 he served as Senior Director, Center for Development of Therapeutics at the Broad Institute, a biomedical and genomic research organization. From June 2010 to January 2015 Dr. Phillips was a Professor of Chemistry at Yale University, and from July 2001 to June 2010 he was Assistant Professor, Associate Professor, and Professor of Chemistry and Biochemistry at the University of Colorado. He holds a B.Sc. in Biochemistry and a Ph.D. in Chemistry from the University of Canterbury in New Zealand. - Andrew J.Phillips担任我们的首席财务官。Phillips博士是Cormorant的董事总经理。他还担任Blossom Bioscience Ltd.的首席执行官。Phillips博士是Onkure，Inc.，Expansion Therapeutics，Inc.，Bivacor，Inc.，Blossom Bioscience，Ltd.，Blossom Biomedicines USA，Inc.和Enliven Therapeutics，Inc.的董事会成员。从2016年到2020年，Phillips博士在C4 Therapeutics, Inc.工作，该公司是一家临床阶段的生物制药公司，专注于治疗癌症和其他疾病，最近的职务是从2018年到2020年担任首席执行官。从2014年到2016年，他担任生物医学和基因组研究组织Broad Institute的治疗学发展中心的高级总监。从2010年到2015年，Phillips博士担任耶鲁大学的化学教授，从2001年到2010年，他担任科罗拉多大学的助理教授，副教授和化学与生物化学教授。他拥有新西兰坎特伯雷大学的生物化学理学士学位和化学博士学位。
- Andrew J. Phillips has served as a Managing Director at Cormorant Asset Management, an investment manager, since August 2020. Since April 2021 he has also served as Chief Financial Officer of Helix and since June 2021 he has also served as Chief Executive Officer of Blossom Bioscience Ltd., and since December 2021 he has also served as interim Chief Executive Officer of Aleksia Therapeutics Inc. Dr. Phillips is a Director at the following private companies: OnKure, Inc., Expansion Therapeutics, Inc., BiVACOR, Inc., Blossom Bioscience, Ltd, Blossom Biomedicines USA, Inc., ONK Therapeutics, Ltd., Kestrel Therapeutics Inc., and Enliven Therapeutics, Inc. Dr. Phillips previously served as a Director at Elevation Oncology, Inc. from November 2020 through June 2021 and Immuneering Corp from December 2020 through July 2021. From January 2016 to March 2020 Dr. Phillips was with C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for the treatment of cancer and other diseases, where he served as Chief Executive Officer from May 2018 to March 2020 President from September 2016 to May 2018 and Chief Scientific Officer from January 2016 to May 2018. From July 2014 to January 2016 he served as Senior Director, Center for Development of Therapeutics at the Broad Institute, a biomedical and genomic research organization. From June 2010 to January 2015 Dr. Phillips was a Professor of Chemistry at Yale University, and from July 2001 to June 2010 he was Assistant Professor, Associate Professor, and Professor of Chemistry and Biochemistry at the University of Colorado. He holds a B.Sc. in Biochemistry and a Ph.D. in Chemistry from the University of Canterbury in New Zealand.
- Jorge Santos da Silva
-
豪尔赫·桑托斯·达席尔瓦，自2022年4月起担任公司首席执行官兼董事。他与人共同创立了MoonLake AG，并从2021年7月起担任其首席执行官，直到合并完成。Santos da Silva博士还担任Minho大学（葡萄牙）医学院的教授和董事会顾问。在共同创立MoonLake AG之前，Santos da Silva博士于2007年9月至2021年6月在咨询公司麦肯锡公司任职，担任高级合伙人，领导了医药和医疗产品实践、生物技术集团和生物仿制药集团，并就企业和业务部门战略、商业运营模式、研发、组织设计、并购和合资企业等方面为国际生物制药和生物技术公司提供建议。Santos da Silva博士是冷泉港实验室的博士后，拥有都灵大学（意大利）的神经元细胞生物学博士学位和格拉斯哥大学生物与生命科学研究所（英国）的分子生物学理学学士学位。他还参加了海德堡（德国）欧洲分子生物学实验室神经生物学方面的工作实习。
Jorge Santos da Silva,has served as Chief Executive Officer and a director of Company since April 2022. He co-founded MoonLake AG and served as its Chief Executive Officer from July 2021 until the Merger Closing. Dr. Santos da Silva also serves as a professor and Board Advisor at the School of Medicine at the Minho University (Portugal). Prior to co-founding MoonLake AG, Dr. Santos da Silva was at McKinsey & Company, Inc., a consulting firm, from September 2007 to June 2021, where he served as Senior Partner and led the Pharmaceutical & Medical Products Practice, the Biotech group and the Biosimilars group and advised international biopharmaceutical and biotechnology companies on corporate and business-unit strategy, commercial operating models, research and development, organizational design, mergers and acquisitions and joint ventures. Dr. Santos da Silva was a Postdoctoral Fellow at Cold Spring Harbor Laboratory and holds a Ph.D. in Neuronal Cell Biology from the University of Turin (Italy) and a B.Sc. in Molecular Biology from the University of Glasgow, Institute of Biological and Life Sciences (United Kingdom). He also participated in a work placement in neurobiology at the European Molecular Biology Laboratory, Heidelberg (Germany). - 豪尔赫·桑托斯·达席尔瓦，自2022年4月起担任公司首席执行官兼董事。他与人共同创立了MoonLake AG，并从2021年7月起担任其首席执行官，直到合并完成。Santos da Silva博士还担任Minho大学（葡萄牙）医学院的教授和董事会顾问。在共同创立MoonLake AG之前，Santos da Silva博士于2007年9月至2021年6月在咨询公司麦肯锡公司任职，担任高级合伙人，领导了医药和医疗产品实践、生物技术集团和生物仿制药集团，并就企业和业务部门战略、商业运营模式、研发、组织设计、并购和合资企业等方面为国际生物制药和生物技术公司提供建议。Santos da Silva博士是冷泉港实验室的博士后，拥有都灵大学（意大利）的神经元细胞生物学博士学位和格拉斯哥大学生物与生命科学研究所（英国）的分子生物学理学学士学位。他还参加了海德堡（德国）欧洲分子生物学实验室神经生物学方面的工作实习。
- Jorge Santos da Silva,has served as Chief Executive Officer and a director of Company since April 2022. He co-founded MoonLake AG and served as its Chief Executive Officer from July 2021 until the Merger Closing. Dr. Santos da Silva also serves as a professor and Board Advisor at the School of Medicine at the Minho University (Portugal). Prior to co-founding MoonLake AG, Dr. Santos da Silva was at McKinsey & Company, Inc., a consulting firm, from September 2007 to June 2021, where he served as Senior Partner and led the Pharmaceutical & Medical Products Practice, the Biotech group and the Biosimilars group and advised international biopharmaceutical and biotechnology companies on corporate and business-unit strategy, commercial operating models, research and development, organizational design, mergers and acquisitions and joint ventures. Dr. Santos da Silva was a Postdoctoral Fellow at Cold Spring Harbor Laboratory and holds a Ph.D. in Neuronal Cell Biology from the University of Turin (Italy) and a B.Sc. in Molecular Biology from the University of Glasgow, Institute of Biological and Life Sciences (United Kingdom). He also participated in a work placement in neurobiology at the European Molecular Biology Laboratory, Heidelberg (Germany).
- Ramnik Xavier
-
Ramnik Xavier，自2022年4月起担任公司董事。自2018年以来，Xavier博士一直担任麻省理工学院和哈佛大学布罗德研究所的核心研究所成员，他还担任Klarman细胞天文台的主任。Xavier博士自2019年起担任布罗德研究所免疫学项目主任，自2016年起担任布罗德传染病和微生物组项目联合主任。自2013年以来，Xavier博士一直担任哈佛医学院的医学教授，目前担任该学院的Kurt J. Isselbacher医学教授。此外，自2018年起，他担任计算和综合生物学中心主任，并担任麻省总医院分子生物学系成员。自2014年起，他还担任麻省理工学院微生物组信息学和治疗中心的联合主任。Xavier博士拥有工商管理硕士学位。（荣誉）津巴布韦大学戈弗雷·哈金斯医学院博士，格罗宁根大学（荷兰）博士。
Ramnik Xavier,has served as a director of Company since April 2022. Since 2018, Dr. Xavier has served as a core institute member of the Broad Institute of MIT and Harvard, where he also serves as Director of the Klarman Cell Observatory. Dr. Xavier has served as Director of the Broad Institute's Immunology Program since 2019 and Co-Director of the Broad's Infectious Disease and Microbiome Program since 2016. Since 2013, Dr. Xavier has served as a Professor of Medicine at Harvard Medical School, where he is currently the Kurt J. Isselbacher Professor of Medicine. In addition, since 2018 he has served as Director of the Center for Computational and Integrative Biology and as a member in the Department of Molecular Biology at Massachusetts General Hospital. He has also served as co-director of the Center for Microbiome Informatics and Therapeutics at MIT since 2014. Dr. Xavier holds an M.B. Ch.B. (Hons.) from the Godfrey Huggins School of Medicine, University of Zimbabwe and a Ph.D. from the University of Groningen (Netherlands). - Ramnik Xavier，自2022年4月起担任公司董事。自2018年以来，Xavier博士一直担任麻省理工学院和哈佛大学布罗德研究所的核心研究所成员，他还担任Klarman细胞天文台的主任。Xavier博士自2019年起担任布罗德研究所免疫学项目主任，自2016年起担任布罗德传染病和微生物组项目联合主任。自2013年以来，Xavier博士一直担任哈佛医学院的医学教授，目前担任该学院的Kurt J. Isselbacher医学教授。此外，自2018年起，他担任计算和综合生物学中心主任，并担任麻省总医院分子生物学系成员。自2014年起，他还担任麻省理工学院微生物组信息学和治疗中心的联合主任。Xavier博士拥有工商管理硕士学位。（荣誉）津巴布韦大学戈弗雷·哈金斯医学院博士，格罗宁根大学（荷兰）博士。
- Ramnik Xavier,has served as a director of Company since April 2022. Since 2018, Dr. Xavier has served as a core institute member of the Broad Institute of MIT and Harvard, where he also serves as Director of the Klarman Cell Observatory. Dr. Xavier has served as Director of the Broad Institute's Immunology Program since 2019 and Co-Director of the Broad's Infectious Disease and Microbiome Program since 2016. Since 2013, Dr. Xavier has served as a Professor of Medicine at Harvard Medical School, where he is currently the Kurt J. Isselbacher Professor of Medicine. In addition, since 2018 he has served as Director of the Center for Computational and Integrative Biology and as a member in the Department of Molecular Biology at Massachusetts General Hospital. He has also served as co-director of the Center for Microbiome Informatics and Therapeutics at MIT since 2014. Dr. Xavier holds an M.B. Ch.B. (Hons.) from the Godfrey Huggins School of Medicine, University of Zimbabwe and a Ph.D. from the University of Groningen (Netherlands).
高管简历
中英对照 | 中文 | 英文- Jorge Santos da Silva
豪尔赫·桑托斯·达席尔瓦，自2022年4月起担任公司首席执行官兼董事。他与人共同创立了MoonLake AG，并从2021年7月起担任其首席执行官，直到合并完成。Santos da Silva博士还担任Minho大学（葡萄牙）医学院的教授和董事会顾问。在共同创立MoonLake AG之前，Santos da Silva博士于2007年9月至2021年6月在咨询公司麦肯锡公司任职，担任高级合伙人，领导了医药和医疗产品实践、生物技术集团和生物仿制药集团，并就企业和业务部门战略、商业运营模式、研发、组织设计、并购和合资企业等方面为国际生物制药和生物技术公司提供建议。Santos da Silva博士是冷泉港实验室的博士后，拥有都灵大学（意大利）的神经元细胞生物学博士学位和格拉斯哥大学生物与生命科学研究所（英国）的分子生物学理学学士学位。他还参加了海德堡（德国）欧洲分子生物学实验室神经生物学方面的工作实习。
Jorge Santos da Silva,has served as Chief Executive Officer and a director of Company since April 2022. He co-founded MoonLake AG and served as its Chief Executive Officer from July 2021 until the Merger Closing. Dr. Santos da Silva also serves as a professor and Board Advisor at the School of Medicine at the Minho University (Portugal). Prior to co-founding MoonLake AG, Dr. Santos da Silva was at McKinsey & Company, Inc., a consulting firm, from September 2007 to June 2021, where he served as Senior Partner and led the Pharmaceutical & Medical Products Practice, the Biotech group and the Biosimilars group and advised international biopharmaceutical and biotechnology companies on corporate and business-unit strategy, commercial operating models, research and development, organizational design, mergers and acquisitions and joint ventures. Dr. Santos da Silva was a Postdoctoral Fellow at Cold Spring Harbor Laboratory and holds a Ph.D. in Neuronal Cell Biology from the University of Turin (Italy) and a B.Sc. in Molecular Biology from the University of Glasgow, Institute of Biological and Life Sciences (United Kingdom). He also participated in a work placement in neurobiology at the European Molecular Biology Laboratory, Heidelberg (Germany).- 豪尔赫·桑托斯·达席尔瓦，自2022年4月起担任公司首席执行官兼董事。他与人共同创立了MoonLake AG，并从2021年7月起担任其首席执行官，直到合并完成。Santos da Silva博士还担任Minho大学（葡萄牙）医学院的教授和董事会顾问。在共同创立MoonLake AG之前，Santos da Silva博士于2007年9月至2021年6月在咨询公司麦肯锡公司任职，担任高级合伙人，领导了医药和医疗产品实践、生物技术集团和生物仿制药集团，并就企业和业务部门战略、商业运营模式、研发、组织设计、并购和合资企业等方面为国际生物制药和生物技术公司提供建议。Santos da Silva博士是冷泉港实验室的博士后，拥有都灵大学（意大利）的神经元细胞生物学博士学位和格拉斯哥大学生物与生命科学研究所（英国）的分子生物学理学学士学位。他还参加了海德堡（德国）欧洲分子生物学实验室神经生物学方面的工作实习。
- Jorge Santos da Silva,has served as Chief Executive Officer and a director of Company since April 2022. He co-founded MoonLake AG and served as its Chief Executive Officer from July 2021 until the Merger Closing. Dr. Santos da Silva also serves as a professor and Board Advisor at the School of Medicine at the Minho University (Portugal). Prior to co-founding MoonLake AG, Dr. Santos da Silva was at McKinsey & Company, Inc., a consulting firm, from September 2007 to June 2021, where he served as Senior Partner and led the Pharmaceutical & Medical Products Practice, the Biotech group and the Biosimilars group and advised international biopharmaceutical and biotechnology companies on corporate and business-unit strategy, commercial operating models, research and development, organizational design, mergers and acquisitions and joint ventures. Dr. Santos da Silva was a Postdoctoral Fellow at Cold Spring Harbor Laboratory and holds a Ph.D. in Neuronal Cell Biology from the University of Turin (Italy) and a B.Sc. in Molecular Biology from the University of Glasgow, Institute of Biological and Life Sciences (United Kingdom). He also participated in a work placement in neurobiology at the European Molecular Biology Laboratory, Heidelberg (Germany).
- Matthias Bodenstedt
Matthias Bodenstedt，自2022年4月起担任公司首席财务官。他此前于2021年7月起担任MoonLake AG的首席财务官，直至合并完成。他分别自2021年9月和2023年11月起担任子公司MoonLake Immunotherapeutics Ltd.（“MoonLake Ltd.”）和MNLK Immunotherapeutics Unipessoal LDA的董事。在加入公司之前，从2011年10月到2021年6月，Bodenstedt先生是德国和瑞士咨询公司麦肯锡公司的合伙人，在那里他为各种各样的客户提供咨询服务，从收入前的生物技术公司到大型全球制药公司。Bodenstedt先生在融资、并购、业务发展和许可、投资组合战略以及上市战略和执行方面拥有丰富的经验。Bodenstedt先生拥有哥伦比亚商学院（纽约）的工商管理硕士学位、剑桥大学（英国）的金融硕士学位和汉诺威大学（德国）的工业工程学士学位。
Matthias Bodenstedt,has served as Chief Financial Officer of Company since April 2022. He previously served as the Chief Financial Officer of MoonLake AG from July 2021 until the Merger Closing. He has served as a director of subsidiaries, MoonLake Immunotherapeutics Ltd. ("MoonLake Ltd.") and MNLK Immunotherapeutics Unipessoal Lda since September 2021 and November 2023, respectively. Prior to joining Company, from October 2011 to June 2021, Mr. Bodenstedt was a Partner at McKinsey & Company, Inc., a consulting firm, in Germany and Switzerland, where he advised a diverse set of clients, ranging from pre-revenue biotechnology companies to large global pharmaceutical companies. Mr. Bodenstedt has experience in financing, mergers and acquisitions, business development and licensing, portfolio strategy, and go-to-market strategy and execution. Mr. Bodenstedt holds an M.B.A. from Columbia Business School (New York), an M.Phil. in Finance from the University of Cambridge (United Kingdom), and B.Sc. in Industrial Engineering from the University of Hannover (Germany).- Matthias Bodenstedt，自2022年4月起担任公司首席财务官。他此前于2021年7月起担任MoonLake AG的首席财务官，直至合并完成。他分别自2021年9月和2023年11月起担任子公司MoonLake Immunotherapeutics Ltd.（“MoonLake Ltd.”）和MNLK Immunotherapeutics Unipessoal LDA的董事。在加入公司之前，从2011年10月到2021年6月，Bodenstedt先生是德国和瑞士咨询公司麦肯锡公司的合伙人，在那里他为各种各样的客户提供咨询服务，从收入前的生物技术公司到大型全球制药公司。Bodenstedt先生在融资、并购、业务发展和许可、投资组合战略以及上市战略和执行方面拥有丰富的经验。Bodenstedt先生拥有哥伦比亚商学院（纽约）的工商管理硕士学位、剑桥大学（英国）的金融硕士学位和汉诺威大学（德国）的工业工程学士学位。
- Matthias Bodenstedt,has served as Chief Financial Officer of Company since April 2022. He previously served as the Chief Financial Officer of MoonLake AG from July 2021 until the Merger Closing. He has served as a director of subsidiaries, MoonLake Immunotherapeutics Ltd. ("MoonLake Ltd.") and MNLK Immunotherapeutics Unipessoal Lda since September 2021 and November 2023, respectively. Prior to joining Company, from October 2011 to June 2021, Mr. Bodenstedt was a Partner at McKinsey & Company, Inc., a consulting firm, in Germany and Switzerland, where he advised a diverse set of clients, ranging from pre-revenue biotechnology companies to large global pharmaceutical companies. Mr. Bodenstedt has experience in financing, mergers and acquisitions, business development and licensing, portfolio strategy, and go-to-market strategy and execution. Mr. Bodenstedt holds an M.B.A. from Columbia Business School (New York), an M.Phil. in Finance from the University of Cambridge (United Kingdom), and B.Sc. in Industrial Engineering from the University of Hannover (Germany).
- Kristian Reich
Kristian Reich，自2022年4月起担任公司首席科学官。他是MoonLake AG的联合创始人，从2021年5月起担任该公司的首席科学官，直到合并完成。Reich博士作为皮肤病学和免疫学领域的全球临床领导者，拥有超过25年的经验，在粘膜和皮肤免疫学领域发表了300多篇同行评审的出版物。他获得了德国过敏和临床免疫学会颁发的赫伯特-赫克斯海默研究奖和美国皮肤病学会颁发的银屑病成就奥斯卡之星奖。Reich博士自2019年4月起担任德国汉堡-埃彭多夫大学医学中心炎症性皮肤病转化研究的客座教授。2005年至2015年，他在私立门诊皮肤科诊所Dermatologikum Hamburg担任管理合伙人，自2013年起担任私立门诊皮肤科诊所Dermatologikum Berlin的自营合伙人。在1996年至2005年期间，他曾在德国格奥尔格-奥古斯特-戈廷根大学皮肤病学系担任多个临床和教学职务，包括最近担任大学教授和皮肤病学系副主任。Reich博士是一名独立医疗董事，也是JeruCON Beratungsgesellschaft mbH Hamburg的创始人，在那里他是一名自营顾问。自2016年起，Reich博士还担任合同研究组织TFS HealthScience的医学顾问。Reich博士还是私营远程皮肤病学公司Derma2go AG（瑞士苏黎世）、私营诊断医疗设备公司Dermagnostix GmbH（德国弗赖堡）和专注于皮肤病学研究的慈善基金会ProDerma Foundation（德国汉堡）的董事会成员。Reich博士于2000年获得皮肤病学和神经病学认证，并于2003年获得过敏学认证。他收到了他的医学博士。慕尼黑工业大学（德国）的医学博士（相当于医学博士）和他的格奥尔格-奥古斯特大学（德国）皮肤病学和神经病学的Venia legendi（相当于博士）。
Kristian Reich,has served as Chief Scientific Officer of Company since April 2022. He is a co-founder of MoonLake AG and served as its Chief Scientific Officer from May 2021 until the Merger Closing. Dr. Reich has more than 25 years of experience as a global clinical leader in dermatology and immunology, with more than 300 peer-reviewed publications in mucosal and skin immunology. He received the Herbert-Herxheimer Research Prize from the German Society for Allergology and Clinical Immunology and the Stars of the Academy Award for achievements in psoriasis from the American Academy of Dermatology. Dr. Reich has served as a Guest-Professor for Translational Research in Inflammatory Skin Diseases at the University Medical Center Hamburg-Eppendorf, Germany, since April 2019. From 2005 to 2015, he served as managing partner at the Dermatologikum Hamburg, a private outpatient dermatology clinic, and he has served as a self-employed partner at the Dermatologikum Berlin, a private outpatient dermatology clinic, since 2013. Between 1996 and 2005, he held several clinical and teaching positions at the Department of Dermatology, Georg-August-University Goettingen, Germany, including most recently serving as University Professor and Vice Director of the Department of Dermatology. Dr. Reich is an independent medical director and founder of JeruCON Beratungsgesellschaft mbH Hamburg, where he is a self-employed consultant. Since 2016, Dr. Reich also serves as a medical advisor for TFS HealthScience, a contract research organization. Dr. Reich is also a member of the board of directors of Derma2go AG (Zürich, Switzerland), a privately held teledermatology company, Dermagnostix GmbH (Freiburg, Germany), a privately-held diagnostic medical device company and ProDerma Foundation (Hamburg, Germany), a charitable foundation focusing on dermatological research. Dr. Reich was accredited in Dermatology and Venerology in 2000 and in Allergology in 2003. He received his Dr. med. (M.D. equivalent) from the Technical University Munich (Germany) and his Venia legendi (Ph.D. equivalent) in Dermatology and Venerology from the Georg-August-University (Germany).- Kristian Reich，自2022年4月起担任公司首席科学官。他是MoonLake AG的联合创始人，从2021年5月起担任该公司的首席科学官，直到合并完成。Reich博士作为皮肤病学和免疫学领域的全球临床领导者，拥有超过25年的经验，在粘膜和皮肤免疫学领域发表了300多篇同行评审的出版物。他获得了德国过敏和临床免疫学会颁发的赫伯特-赫克斯海默研究奖和美国皮肤病学会颁发的银屑病成就奥斯卡之星奖。Reich博士自2019年4月起担任德国汉堡-埃彭多夫大学医学中心炎症性皮肤病转化研究的客座教授。2005年至2015年，他在私立门诊皮肤科诊所Dermatologikum Hamburg担任管理合伙人，自2013年起担任私立门诊皮肤科诊所Dermatologikum Berlin的自营合伙人。在1996年至2005年期间，他曾在德国格奥尔格-奥古斯特-戈廷根大学皮肤病学系担任多个临床和教学职务，包括最近担任大学教授和皮肤病学系副主任。Reich博士是一名独立医疗董事，也是JeruCON Beratungsgesellschaft mbH Hamburg的创始人，在那里他是一名自营顾问。自2016年起，Reich博士还担任合同研究组织TFS HealthScience的医学顾问。Reich博士还是私营远程皮肤病学公司Derma2go AG（瑞士苏黎世）、私营诊断医疗设备公司Dermagnostix GmbH（德国弗赖堡）和专注于皮肤病学研究的慈善基金会ProDerma Foundation（德国汉堡）的董事会成员。Reich博士于2000年获得皮肤病学和神经病学认证，并于2003年获得过敏学认证。他收到了他的医学博士。慕尼黑工业大学（德国）的医学博士（相当于医学博士）和他的格奥尔格-奥古斯特大学（德国）皮肤病学和神经病学的Venia legendi（相当于博士）。
- Kristian Reich,has served as Chief Scientific Officer of Company since April 2022. He is a co-founder of MoonLake AG and served as its Chief Scientific Officer from May 2021 until the Merger Closing. Dr. Reich has more than 25 years of experience as a global clinical leader in dermatology and immunology, with more than 300 peer-reviewed publications in mucosal and skin immunology. He received the Herbert-Herxheimer Research Prize from the German Society for Allergology and Clinical Immunology and the Stars of the Academy Award for achievements in psoriasis from the American Academy of Dermatology. Dr. Reich has served as a Guest-Professor for Translational Research in Inflammatory Skin Diseases at the University Medical Center Hamburg-Eppendorf, Germany, since April 2019. From 2005 to 2015, he served as managing partner at the Dermatologikum Hamburg, a private outpatient dermatology clinic, and he has served as a self-employed partner at the Dermatologikum Berlin, a private outpatient dermatology clinic, since 2013. Between 1996 and 2005, he held several clinical and teaching positions at the Department of Dermatology, Georg-August-University Goettingen, Germany, including most recently serving as University Professor and Vice Director of the Department of Dermatology. Dr. Reich is an independent medical director and founder of JeruCON Beratungsgesellschaft mbH Hamburg, where he is a self-employed consultant. Since 2016, Dr. Reich also serves as a medical advisor for TFS HealthScience, a contract research organization. Dr. Reich is also a member of the board of directors of Derma2go AG (Zürich, Switzerland), a privately held teledermatology company, Dermagnostix GmbH (Freiburg, Germany), a privately-held diagnostic medical device company and ProDerma Foundation (Hamburg, Germany), a charitable foundation focusing on dermatological research. Dr. Reich was accredited in Dermatology and Venerology in 2000 and in Allergology in 2003. He received his Dr. med. (M.D. equivalent) from the Technical University Munich (Germany) and his Venia legendi (Ph.D. equivalent) in Dermatology and Venerology from the Georg-August-University (Germany).